Tirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension: A Randomized, Double-Masked, Placebo-Controlled Phase 2 Trial of Adjunctive Tirzepatide
Brigham and Women's Hospital
Summary
The goal of this clinical trial is to learn if tirzepatide, a dual GIP/GLP-1 receptor agonist, helps to treat idiopathic intracranial hypertension (IIH) when added to acetazolamide, which is the standard medical therapy for IIH. The main questions it aims to answer are: * Does tirzepatide lower the mean daily acetazolamide dose at 12 months? * Does tirzepatide add-on therapy improve the likelihood of remission of IIH, improve weight loss, reduce cumulative acetazolamide exposure, improve ophthalmic outcome measures, improve normalization of intracranial hypertension as measured by lumbar puncture (LP) opening pressure, improve headache and quality of life measures and, improve MRI findings of intracranial hypertension? Investigators will compare tirzepatide to a placebo/sham injection in patients who are treated with a predefined dosing schedule of acetazolamide that adjusts based upon the response of papilledema and other IIH symptoms such as headache. In addition to receiving treatment with acetazolamide, participants will: * Receive weekly tirzepatide injections or a placebo/sham injection for 12 months, followed by 12 months of open-label observation. * Attend clinic visits at enrollment and months 1, 2, 3, 5, 7, 10, and 12 for neuro-ophthalmic examination and testing. * During other months meet with investigator or research assistant by phone for symptom documentation and medication adjustment. * Keep a record of any significant of days with headache for more than three hours or when a medication was taken for acute treatment of headache.
Description
Background. Acetazolamide is the current standard medical therapy for IIH and acts through inhibiting CSF production by the choroid plexus epithelium. The IIH Treatment Trial showed that acetazolamide improves visual field mean deviation, papilledema, and weight loss versus placebo, but the absolute effects were modest, headache was not significantly improved, and tolerability of acetazolamide remains a limitation. Tirzepatide and other GLP-1 agonists have potential benefit in IIH since they are effective for weight loss, and IIH can be put into remission with roughly 25% weight loss. Direct l…
Eligibility
- Age range
- 18–55 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * IIH with papilledema, adapted from the 2013 diagnostic criteria and the modified Dandy criteria used in the IIH Treatment Trial: (i) Papilledema confirmed by a neuro-ophthalmologist (ii) Lumbar puncture opening pressure \>25 cm CSF within 6 weeks of enrollment with normal CSF constituents; if opening pressure is 20-25 cm CSF, at least one of: venous pulsatile tinnitus, sixth cranial nerve palsy, Frisén grade ≥2 papilledema with pseudopapilledema excluded in at least one eye, or bilateral transverse venous sinus stenosis (iii) MRI and MRV of the brain showing no cause…
Interventions
- DrugTirzepatide
Weekly subcutaneous self-injection via autoinjector, starting 1 week after acetazolamide initiation at 2.5 mg and increasing every month to 5, 7.5, 10, 12.5, and 15 mg weekly as tolerated. Down-titration by one step and discontinuation at 2.5 mg are allowed for intolerance. Other names: Mounjaro; Zepbound.
- DrugPlacebo
Weekly subcutaneous placebo injection matched to tirzepatide in appearance and delivery device, with the same dose-escalation schedule.
- DrugAcetazolamide
Extended-release capsules, starting at 500 mg twice daily (or 1,000 mg twice daily for Frisén grade 3 papilledema or PMD worse than -7 dB), titrated at study visits in 500 mg steps by predefined rules, maximum 4 g/day.
Location
- Brigham and Women's HospitalBoston, Massachusetts